Artificial Organs & Medical Devices
Total artificial hearts. Wearable kidneys. Implantable lungs. Neuroprosthetic eyes. The $31 billion artificial organ market is delivering life-saving solutions where biology fails — and OrganLabs.com names the laboratories driving that progress.
Artificial Organ Categories
The artificial organ field spans every major organ system — from cardiovascular devices already saving tens of thousands of lives annually to next-generation neurological and sensory prosthetics at the cutting edge of bioelectronic medicine.
From the Jarvik-7 in 1982 to the SynCardia and CARMAT devices today — total artificial hearts are implanted as bridge-to-transplant devices. Next-generation designs aim for permanent implantation with 10+ year device lifetimes and elimination of external power sources.
Over 800,000 VADs have been implanted worldwide, supporting left or right ventricular function in end-stage heart failure patients. HeartMate 3 and HVAD devices represent the current clinical standard; next-gen miniaturised and transcutaneous devices are in advanced development.
Extracorporeal membrane oxygenation saved tens of thousands of COVID-19 patients. Ambulatory artificial lungs — wearable devices that enable patients to walk while receiving respiratory support — are moving through clinical trials with promising results.
The Kidney Project at UCSF is developing a fully implantable bioartificial kidney combining silicon nanopore membranes with living tubule cells. If successful, it could eliminate dialysis for the 800,000 Americans on renal replacement therapy, transforming quality of life.
Retinal implants restoring partial vision. Cochlear implants providing hearing. Brain-computer interfaces enabling paralysed patients to communicate. The bioelectronic medicine frontier where artificial organs intersect with neural engineering.
Closed-loop insulin delivery systems — combining continuous glucose monitors with automated insulin pumps — now approved as "artificial pancreas" devices. Fully implantable next-generation versions combining islet cells with bioartificial encapsulation are in clinical trials.
The $31 Billion Market
The artificial organ market will reach $31 billion by 2028, growing at 8.5% CAGR. It spans cardiovascular devices, renal replacement, respiratory support, endocrine prosthetics and sensory implants — an extraordinarily diverse field unified by a single mission: replacing failing biological organs with engineered alternatives.
The companies competing in this market — from Medtronic and Abbott to CARMAT and The Kidney Project — are not merely engineering products. They are building laboratories of organ function. They are, in every meaningful sense, organ labs.
The acquirer of OrganLabs.com names this entire market in two words — and positions themselves at its apex from the moment of acquisition.
Acquire OrganLabs.com →Market Segments
● The artificial organ domain — available for acquisition ●